Site Search

Displaying results 71 - 80 of 97

03/12/2021

Governing Board

The Governing Board is the main decision-making body of IHI.

25/11/2021

From IMI to IHI

We transitioned from IMI to IHI at the end of 2021, but what changed, and what stayed the same?

WEB-RADR

Recognising Adverse Drug Reactions

Breast cancer image by Emily frost via Shutterstock

25/02/2022

The opportunities and challenges of cancer-on-chip models in immunotherapy

IMI-funded IMSAVAR reviewed the state of ‘cancer-on-chip’ technology. While promising, problems with manufacturing to scale make them impractical for the moment.

WEB-RADR 2

Closed IMI2 Tools for predicting/monitoring safety Big data and knowledge management Real-world data, evidence Regulatory and HTA processes Methods for benefit/risk assessment

VITAL

Vaccines and infectious diseases in the ageing population

Ongoing IMI2 Ageing-associated diseases Infectious diseases Vaccines Tools for predicting/monitoring efficacy Real-world data, evidence

Physio being performed by healthcare worker on prone patient. Image by ESB Professional via shutterstock

14/12/2021

Computational modelling shows promise for predicting mortality risk after knee surgery

Some people are at higher risk than others of dying after the common procedure. EHDEN’s modelling was able to identify them

Multiple people's hands reaching together as viewed from above. Image by Rawpixel.com via Shutterstock

27/04/2023

IHI seeks patients and caregivers to contribute to its activities

IHI is calling on patients and informal caregivers to apply to be part of a new IHI Patient Pool which will strengthen IHI’s ties with the patient community, and make it easier to...

07/12/2021

Research and innovation agenda

The document details the areas IHI should work on and guides IHI’s decisions on call topics.

Salina and her son Tyler are both living with NF. Image courtesy of the Children's Tumor Foundation.

24/01/2024

Game-changing trial for children with tumours being established thanks to EU-PEARL

The Children’s Tumor Foundation and the Global Coalition for Adaptive Research are making EU-PEARL’s model for a platform trial for patients with neurofibromatosis-1 (NF-1) and...